---
layout: default
title: Levothyroxine Sodium
parent: 僅模型預測 (L5)
nav_order: 201
evidence_level: L5
indication_count: 0
---

# Levothyroxine Sodium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Levothyroxine Sodium: Thyroid Hormone Replacement — Repurposing Analysis Pending

## One-Sentence Summary

Levothyroxine Sodium is a synthetic thyroid hormone used as replacement therapy for hypothyroidism and related thyroid conditions, with 9 registered products currently on the Malaysian market.
The current Evidence Pack contains **no TxGNN predictions** for new indications — the prediction pipeline has not returned candidates for this drug.
This report is classified as **data-insufficient** and cannot proceed to full repurposing analysis until the identified data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Hypothyroidism / thyroid hormone replacement |
| Predicted New Indication | — (No predictions available) |
| TxGNN Prediction Score | — |
| Evidence Level | — (Prediction pipeline incomplete) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 9 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predictions are present in this Evidence Pack — the `predicted_indications` array is empty. This means either the prediction pipeline has not completed for this drug, or no candidates met the minimum scoring threshold. Without a target indication, no mechanistic rationale can be formally evaluated.

Based on general pharmacological knowledge, Levothyroxine Sodium is a synthetic form of thyroxine (T4), the primary hormone secreted by the thyroid gland. In the body, T4 is peripherally converted to the more active triiodothyronine (T3), which binds to nuclear thyroid hormone receptors and regulates gene expression governing metabolism, cardiovascular function, growth, and neurological development. Potential repurposing candidates could theoretically span metabolic syndrome, heart failure, or cognitive disorders — but no formal model predictions currently exist to substantiate or prioritise any specific direction.

Detailed mechanism of action data from DrugBank is also unavailable in this pack (see Data Gaps below), which further limits any mechanistic cross-indication analysis. Re-running the full TxGNN pipeline with complete drug inputs is the necessary first step before any repurposing assessment can be made.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted new indication is available for evidence retrieval.

---

## Literature Evidence

Currently no related literature available — no predicted new indication is available for evidence retrieval.

---

## Malaysia Market Information

9 product registrations were identified by NPRA query, but individual product details (licence number, product name, dosage form, approved indication) were not populated in the current data pack and require a separate retrieval step.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|--------------|-------------|---------------------|
| — | — | — | Details not available in current data pack |

> **Note:** NPRA query returned 9 results (query log ID 1, status: success). A follow-up retrieval of individual product records is needed to populate this table.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Two data gaps of Blocking and High severity are unresolved, no TxGNN predictions have been generated, and individual licence details remain unpopulated — the evidence base is currently insufficient to support any repurposing recommendation.

**To proceed, the following is needed:**

- **[Blocking — DG001] Package insert warnings and contraindications** — Download and parse the NPRA package insert PDF(s) for Levothyroxine Sodium to extract key warnings, contraindications, and DDI information; this is a prerequisite for safety pre-screening
- **[High — DG002] Mechanism of action (MOA)** — Query the DrugBank API to retrieve DrugBank ID, MOA, pharmacodynamics, and drug categories; this is required for mechanistic cross-indication analysis
- **Re-run TxGNN prediction pipeline** — Once drug-level data inputs are complete, re-execute the KG and deep-learning prediction steps to generate repurposing candidates with scored indications
- **Populate NPRA licence details** — Retrieve individual product records for the 9 registered products (product name, dosage form, approved indications) to complete the Malaysia Market Information section
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

